Global CMO & CDMO Market Growth (Status and Outlook) 2023-2029

Global CMO & CDMO Market Growth (Status and Outlook) 2023-2029

At a time when pharmaceutical companies face increasing price pressures around the globe from key payers, including public and government insurance systems, reducing operational expenses is a major driver of outsourcing pharmaceutical manufacturing to CDMOs. Also, an increasing number of pharmaceutical companies are refocusing on their core capabilities and strengths, leading to divestments of in-house manufacturing capacities in some areas and to a gro

LPI (LP Information)' newest research report, the “CMO & CDMO Industry Forecast” looks at past sales and reviews total world CMO & CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected CMO & CDMO sales for 2023 through 2029. With CMO & CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CMO & CDMO industry.

This Insight Report provides a comprehensive analysis of the global CMO & CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CMO & CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CMO & CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CMO & CDMO and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CMO & CDMO.

The global CMO & CDMO market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for CMO & CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for CMO & CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for CMO & CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key CMO & CDMO players cover Recipharm, AMRI3, Patheon, Aenova, Catalent, Amatsigroup, WuXi PharmaTech, Strides Shasun and Piramal, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of CMO & CDMO market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Development
API production
Formulation

Segmentation by application
Pharmaceutical Industry
Biotechnology
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Recipharm
AMRI3
Patheon
Aenova
Catalent
Amatsigroup
WuXi PharmaTech
Strides Shasun
Piramal
Siegfried

Please note: The report will take approximately 2 business days to prepare and deliver.